### 1 Quality of life and associated factors among HIV positive patients after completion of

### 2 treatment for Cryptococcal meningitis

- 3 Authors: Jonathan Kitonsa<sup>1\*</sup>, Julius Kiwanuka<sup>2</sup>, Zacchaeus Anywaine<sup>1</sup>, Sheila Kansiime<sup>1</sup>,
- 4 Kenneth Katumba<sup>1</sup>, Namirembe Aeron<sup>1</sup>, Justin Beardsley<sup>3,4</sup>, Freddie Kibengo<sup>1</sup>, Alastair
- 5 Gray<sup>5</sup>, Pontiano Kaleebu<sup>1</sup>, Jeremy Day<sup>3, 6</sup>

### 6 Institutions

- 7 1 Medical Research Council / Uganda Virus Research institute & London School of Hygiene
- 8 and Tropical Medicine Uganda Research Unit
- 9 2 Department of Epidemiology and Biostatistics, School of Public Health, Makerere
- 10 University Kampala, Uganda
- 11 3. Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme
- 12 Vietnam, Ho Chi Minh City, Vietnam
- 13 4. Marie Bashir Institute, Westmead Clinical School, University of Sydney, Australia
- 14 5. Health Economics Research Centre, Nuffield Department of Population Health, University
- 15 of Oxford, Oxford, UK
- 16 6. Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus,
- 17 Headington, Oxford OX3 7BN UK
- 18

19

### 20 \* Corresponding author

- 21 Email: Jonathan.Kitonsa@mrcuganda.org, jonathankitonsa@yahoo.com (JK)
- 22
- 23
- 24

# 25 Abstract

**Background:** Cryptococcal meningitis (CCM) remains one of the leading causes of mortality among HIV infected patients. Due to factors such as the severity of CCM pathology, the quality of life (QOL) of patients post-treatment is likely to be poor. Few studies have reported on QOL of CCM patients post treatment completion. We used data collected among patients in the CryptoDex trial (ISRCTN59144167) to determine QOL and associated factors at week 10 and six months from treatment initiation.

Methodology: CryptoDex was a double-blind placebo-controlled trial of adjunctive dexamethasone in HIV infected adults with CCM, conducted between 2013 and 2015 in six countries in Asia and Africa. QOL was determined using the descriptive and Visual Analog Scales (VAS) of the EuroQol Five-Dimension-Three-Level (EQ-5D-3L) tool. We derived index scores, and described these and the VAS scores at 10 weeks and 6 months; and used linear regression to determine the relationship between various characteristics and VAS scores at both time points.

39 **Results:** Of 451 patients enrolled in the trial, 238 had QOL evaluations at week 10. At 40 baseline, their mean age (SD) was 35.2(8.5) years. The overall mean VAS score (SD) at 10 41 weeks was 57.2 (29.7), increasing significantly to 72(27.4) at month six (p<0.001). The 42 overall mean VAS score (SD) at week 10 was 57.2(29.7), increasing significantly to 72(27.4) 43 at month six, (p < 0.001). At week 10, higher VAS score was associated with absence of confusion 44 (p=0.039), greater weight (p=0.002), and being African (p<0.001). At month six, higher VAS score 45 remained associated with African origin (p=0.019). Higher number of inpatient days was 46 associated with worse VAS scores at 10 weeks and 6 months (p<0.001 and p=0.00647 respectively).

48 Conclusion: QOL was good among patients that had completed therapy for CCM, but
49 below perfect. Strategies to improve QOL among CCM survivors are required.
50 Key words: Quality of life, Cryptococcal meningitis, HIV, Treatment completion
51

# 52 Lay summary

In spite of the remarkable reduction in the incidence of Cryptococcal meningitis (CCM), with increased use of antiretroviral therapy, incidence remains unacceptably high especially in sub-Saharan Africa and Asia where more than 90% of the cases and deaths occur.

56 Due to factors such as the severity of CCM pathology, the quality of life (QOL) of patients 57 post-treatment is also likely to be poor. Few studies have reported on QOL of CCM patients 58 post treatment completion. We used data collected among patients in the CryptoDex trial 59 (ISRCTN59144167) to determine self-perceived QOL and associated factors among 238 50 survivors at week 10 and 203 survivors at six months from treatment initiation.

We determined QOL using the descriptive and Visual Analog Scales (VAS) of the EuroQol
Five-Dimension-Three-Level (EQ-5D-3L) tool.

We found that while self-perceived QOL was only relatively good among this cohort of patients who had survived through treatment for CCM, it continued to improve over the 6 months following diagnosis. Low weight at diagnosis, prolonged hospital admission, and being Asian were associated with lower QOL. QOL is an important outcome that should be considered among HIV infected patients treated for serious infections such as CCM.

68

69

70

72

73

# 74 Introduction

75 Cryptococcal meningitis (CCM) is one of the leading causes of mortality among HIV 76 infected patients, especially in sub-Saharan Africa and Asia. Mortality from CCM remains 77 high, in spite of a significant reduction in the incidence of opportunistic infections (OIs), 78 resulting from improvement in HIV management including early initiation of antiretroviral 79 therapy (ART) [1]. Between 2009 and 2014, the estimated global annual prevalence and 80 mortality due to CCM reduced from 975,900 to 223,100 and 624,700 to 181,100 respectively 81 [2,3]. While incidence, prevalence, and mortality indices have been used widely to 82 demonstrate the burden of CCM amongst HIV infected patients, its effects on other important 83 measures of health such as quality of life (QOL) have not been adequately evaluated. Due to 84 the advanced stage of AIDS at which CCM occurs, severity of disease pathology, toxicity of 85 antifungal medications and disease sequelae, the QOL post-treatment is likely to be poor. We 86 previously showed that patients with low QOL at treatment completion are more likely to die 87 two years later than those with higher QOL[4]. Previous research has demonstrated that QOL 88 measurements amongst HIV infected patients should be done routinely [5-8], since improved 89 QOL is one of the ultimate goals of HIV management. We used data collected from patients 90 enrolled in the CryptoDex trial (PMID: 25391338, ISRCTN59144167) [9,10] to determine 91 QOL at 10 weeks and six months since treatment initiation and the factors associated with 92 QOL at 10 weeks and six months.

93

94

96 97

98

# 99 Methodology

## 100 Study design and setting

101 The CryptoDex trial was a double-blind placebo-controlled phase III trial of adjunctive 102 dexamethasone in HIV infected adults with cryptococcal meningitis. The study was 103 conducted between 2013 and 2015 at thirteen sites in six countries in Asia and Africa 104 (Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi).

## 105 Subjects enrolled in the CryptoDex study and their management

106 Patients recruited in the CryptoDex study were 18 years and above, had HIV infection, a 107 clinical syndrome consistent with CCM, and microbiological confirmation of disease, as 108 indicated by one or more of the following test results: 1) positive India ink staining of 109 cerebral spinal fluid (CSF); 2) culture of Cryptococcus species from CSF or blood; or 3) 110 cryptococcal antigen detected in CSF on cryptococcal antigen lateral flow assay (IMMY). 111 Exclusion criteria included pregnancy, renal failure, gastrointestinal bleeding, having been 112 treated with more than 7 days of anticryptococcal antifungal therapy, and being on or 113 requiring glucocorticoid therapy for coexisting conditions. Informed consent was obtained 114 from all patients or a next of kin where a patient was not in position to consent. Eligible 115 patients were randomised in a 1:1 ratio, stratified by site, to receive either dexamethasone 116 adjunctive therapy or placebo in a tapered dose until 42 days post-randomisation. Details of 117 other study procedures and investigations can be found in the CryptoDex study protocol [11]. 118 The treatment regimen included an induction phase with intravenous Amphotericin B (1) 119 mg/kg/day) and oral Fluconazole 800mg daily for 14 days, followed by a continuation phase

of 800mg daily fluconazole for eight weeks, and then a maintenance phase with oral fluconazole 200mg daily. This regimen was consistent with the WHO treatment recommendation for settings where Flucytosine was not available at the time the trial was conducted [12].

Patients were followed up in the study until six months after enrolment, at which point theywere exited and referred back to their HIV care clinics for continuation of HIV care.

# 126 Subjects included in this analysis

127 This QOL analysis includes patients who survived up to 10 weeks post-treatment initiation 128 when the first QOL assessment was performed. A second QOL assessment was done at 129 month six and therefore patients who had not died between 10 weeks and six months and 130 were accessible i.e., able to come to the clinics, are included in the six months analysis.

## 131 Variables and their measurement in the CryptoDex study

132 Quality of life was measured using the EQ-5D-3L tool [13]. This tool gives a subjective 133 measure for the QOL, which is in line with the definition of QOL by WHO. The WHO 134 defines QOL as an individuals' perception of their position in the context of culture and value 135 systems in which they live and in relation to their goals, expectations, standards, and 136 concerns [14]. The tool is a widely used measure of health status consisting of two parts. The 137 first part (the descriptive system) assesses health in five dimensions (mobility, self-care, usual 138 activities, pain/discomfort, and anxiety/depression). Each dimension has three levels of 139 response (no problems, some problems, extreme problems/not able to). This part of the EQ-140 5D-3L questionnaire provides a descriptive profile that can be used to generate a health state 141 profile. For example, a patient in health state 11233 would have no problems in mobility and 142 self-care, some problems with usual activities, severe/extreme pain/discomfort, and extreme 143 anxiety or depression. Each health state is assigned a summary index score based on societal

144 preference weights for the health state. Heath state index scores generally range from less 145 than 0 (where 0 is a health state equivalent to death; negative values are valued as worse than 146 death) to 1 (perfect health). Health state preferences can differ between countries. Where a 147 value set is not available for a country/region, the assessor can opt to select a value set for a country/region considered to most closely approximate the country of interest [13]. We used 148 149 the Thailand value set for sites in Asia (Vietnam, Thailand, Indonesia and Laos) [15] and the 150 Zimbabwe value set for sites in Africa (Uganda and Malawi) [16]. The second part of the 151 EQ-5D-3L questionnaire consists of a visual analog scale (VAS) on which the patient rates 152 his/her self-perceived health from 0 (the worst imaginable health) to 100 (the best imaginable 153 health/perfect health).

The tool was translated into the local languages and administered by a study doctor who read the questions to the patient. Other details concerning its administration can be found in the study protocol [11].

We measured the impact of a number of variables on QOL measured using the VAS score including: demographic characteristics (age, sex, and education measured as number of years in school); continent, i.e. Asia or Africa; ART status, i.e. on or not on ART; time on ART; most recent CD4 count at enrolment; presence of convulsions; intervention arm, i.e., dexamethasone or placebo; Number of inpatient days by week 10 and month six, baseline CSF fungal burden, and Number of adverse events (neurological events, new AIDs defining illnesses, other adverse events, and immune reconstitution syndrome events).

- 164
- 165
- 166
- 167
- 168

### **Data Analysis**

All data from the CryptoDex study was derived from the secure OUCRU proprietary CLIRES
trial database. Data were extracted into a Microsoft Access database for export to STATA
(College Station, TX, version 15.0). Categorical variables were summarised by frequencies
and percentages, while continuous variables were summarised using means (standard
deviations) and/or medians (interquartile ranges).

175 A health profile was generated by continent and time points (i.e., week 10 and month six), 176 from which we derived a health state index score using the selected value sets for each 177 region. We then summarised the index scores by means, standard deviations (SD), and 178 minimum and maximum scores by continent at the different time points. VAS scores were 179 interpreted as very good (81-100), good (51-80), normal (31-50) and bad/very bad (0-30) [17]. T-tests were used to compare VAS scores between continents and to test for significant 180 181 changes in VAS scores and index scores at the different time points. We also computed and 182 presented percentages of categories under each of the five dimensions of the EQ-5D-3L 183 questionnaire.

We used simple linear regression to determine crude associations between VAS scores at week 10 and month six and various variables. This analysis was not repeated using index scores as two value sets (Thailand and Zimbabwe) were used, and sample sizes were too small to conduct separate analyses. Variables that had a p-value of 0.2 and below at univariate analysis were included in a multivariable linear regression model. Variables were retained in the multivariable model if their inclusion did not make the model significantly worse at LRT p-value 0.05.

#### **Ethical considerations** 191

- 192 The CryptoDex study received ethical approval from each country's respective regulatory
- 193 authorities, and the Oxford Tropical Ethics Committee as indicated in the published protocol
- 194 and study paper [9,10].

#### **Results** 195

196 \* Patients were not able to come to clinics to have QOL assessment.

The baseline characteristics are summarised in Table 1.

#### 197 Fig 1: Flow diagram showing participants enrolled in CryptoDex trial who had quality of life evaluations done. 198

199

#### **Baseline Characteristics:** 200

201 Figure 1 is a flow diagram showing the patients included in this analysis. Out of 823 patients 202 screened at the 13 sites globally, 451 were found eligible and randomized. One patient was 203 subsequently excluded because he never received the assigned study drug due to an 204 administrative error. Out of the remaining 450 patients, 251 (55.8%) survived to week 10 205 post-treatment initiation, and 238 (94.8%) completed a QOL assessment and were included in 206 our analysis. The other 13 (5.2%) patients were not accessible for the quality of life 207 assessment since they did not come to the clinics. At baseline, the mean age (SD) of the 238 208 patients was 35.2 (8.5) years, and 101 (42.4%) were on ART. The median CD4 count (IQR) 209 was 30 (13, 71) cells/ml. Thirty (12.6%) patients reported a history of convulsions. Of the 210 238 patients, 113 (47.5%) had been randomised to receive dexamethasone adjunctive therapy. 211

## 212 Adverse events:

- 213 Four hundred and thirty four adverse events were captured among these participants,
- 214 including 67 new neurological events, 93 new AIDs defining illnesses, 365 other adverse
- events, and 9 immune reconstitution syndrome events.
- 216
- 217
- 218
- 219

### 220 Table 1: Baseline characteristics of the patients that had QOL evaluation at 10 weeks

		Africa	Asia	Overall
Variable	Level	Frequency (%)	Frequency (%)	Frequency (%)
Gender (n=238)	Male	71(57.3)	81(71.1)	152(63.9)
	Female	53(42.7)	33(29.0)	86(36.1)
Mean age (SD), (n=238)		34.9(8.7)	35.7(8.3)	35.2(8.5)
Median CD4 (IQR), (n=126)*		40(15, 104)	25(9, 51)	30(13, 71)
Years in school (n=215)**	<u>≤</u> 7	63(57.3)	44(41.9)	107(49.8)
	>7	47(42.7)	61(58.1)	108(50.2)
Glasgow coma Score	15+	107(86.3)	103(90.4)	210(88.2)
(n=238)	<15	17(13.7)	11(9.6)	28(11.8)
Period known to have HIV in years (179)		0.5(0.2, 2)	0.2(0.1, 1.9)	0.4(0.1, 1.9)
On ARVs (n=238)	No	53(42.7)	84(73.7)	137(57.6)
	Yes	71(57.3)	30(26.3)	101(42.4)
Confusion (n=238)	No	83(66.9)	97(85.1)	180(75.6)
	Yes	41(33.1)	17(14.9)	58(24.4)
Mean Weight (SD) (n=238)		52.7(10.8)	51.5(9.3)	52.1(10.1)
Convulsion (n=238)	No	117(94.3)	91(79.8)	208(87.4)
	Yes	7(5.7)	23(20.2)	30(12.6)
Intervention (n=238)	Dexamethasone	55(44.4)	58(50.9)	113(47.5)
	Placebo	69(55.6)	56(49.1)	125(52.5)
CSF Culture, CFU/ml	<1000cfu/ml	47(39.8)	31(28.4)	78(34.4)
$(n=227)^{***}$	≥1000cfu/ml	71(60.2)	78(71.6)	149(65.6)
11 · 4 · NT 1		: 1 /1 (D		TT

221 Abbreviations: n, Number; ARVs, Anti retro viral therapy; SD, Standard deviation; HIV, Human

222 immunodeficiency virus; %, percentage; CFU/ml, Colony forming units per millilitre.

223 \*Pre-enrolment CD4s considered. CD4s were not repeated in the study. Some patients had no record of CD4 224

counts.

- 225 \*\*Responses could not be got for some participants because of altered consciousness.
- 226 \*\*\*Lumbar punctures were not successful in a few patients.
- 227

#### **Quality of life assessment** 228

229 **Descriptive system and index scores:** Health profile results for patients at both time points 230 are summarised in Table 2. There was no difference in the proportion of patients from Africa 231 or Asia rating themselves as having perfect health (i.e., profile 11111) at 10 weeks (Africa: 232 40 of 124 (32.3%); Asia: 37 of 114 (32.5%)). At this time point, 4 Asian patients (3.5%) rated 233 themselves as having the worst health state possible i.e. 33333 compared with 1 African 234 patient (0.8%, p=0.2). At month six, reported quality of life had increased in both African and 235 Asian centres, with 58 of 104 (55.8%) Africans and 48 of 99 (48.5%) Asians rating 236 themselves as having perfect health (p=0.2).

237 At week 10, the mean index scores (SD, range) were 0.785 (0.2, -0.145 to 1) and 0.619 (0.4, -

238 0.452 to 1) for African and Asian patients respectively, increasing significantly at month six,

239 to 0.879 (0.2, 0.341 to 1), p=0.002 and 0.731 (0.4, -0.452 to 1), p=0.052 for African and

- 240 Asian patients respectively.
- 241 242 Table 2: Health profile scores for patients at week 10 and month six

CONTINENT	Level	Mobility		Self-care		Usual activities		Pain/discomfort		Anxiety/ depression	
		Week	Month	Week 10	Month	Week	Month	Week	Month	Week	Month
		10	six	n (%)	six	10	six	10	six	10	six
		n (%)	n (%)		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
AFRICA	1(no	79(63.7)	84(80.8)	102(82.3)	99(95.2)	59(51.8)	72(69.2)	72(58.1)	75(72.1)	78(63.4)	79 (76)

	problems)										
	2(some problems)	39(31.5)	20(19.2)	14(11.3)	4(3.8)	35(30.7)	25(24.1)	47(37.9)	28(26.9)	37(30.1)	21(21.1)
	3(extreme problems)	6(4.8)	0	8(6.4)	1(1)	20(17.5)	7(6.7)	5(4)	1(1)	8(6.5)	3(2.9)
ASIA	1(no problems)	71(62.3)	72(72.7)	83(72.8)	85(85.9)	59(51.8)	68(68.7)	60(53.1)	61(61.6)	76(68.5)	<b>69(70.4</b> )
	2(some problems)	28(24.5)	22(22.2)	16(14)	8(8.1)	35(30.7)	20(20.2)	42(37.2)	33(33.3)	28(25.2)	22(22.5)
	3(extreme problems)	15(13.2)	5(5.1)	1 (13.2)	6(6)	20(17.5)	11(11.1)	11(9.7)	5(5.1)	7(6.3)	7(7.1)

243 Abbreviations: n, Number; %, percentage.

### **EQ VAS scale results**

The overall mean VAS score (SD) at 10 weeks was 57.2 (29.7), increasing significantly to 72

246 (27.4) at month six (p<0.001), both mean scores falling within category 51-80, i.e. "Good

247 QOL". The mean score (SD) at 10 weeks was significantly higher among African patients

than Asian patients i.e., 65.7 (21.5) vs 47.5 (34.5), p<0.001. Similarly the mean score (SD) at

six months was significantly higher among African patients compared to Asian patients i.e.,

250 79 (17.7) vs 64.2 (33.4), p<0.001.

251 Mean VAS and Index scores at week 10 and month six are represented in Figure 2.

252

253 Abbreviations: VAS, Visual analog scale; QoL, Quality of life.

Fig 2: Mean VAS scores and Index scores at week 10 and 6 months after treatment initiation

256

## 257 Factors associated with quality of life

258 Results from the univariate and multivariate analysis are summarised in Table 3.

259	At week 10, the baseline factors associated with higher VAS score at multivariate analysis
260	were: greater weight (regression coefficient 0.6, 95% CI: 0.2 to 1), p=0.002; and being from
261	Africa (regression coefficient 15.6, 95% CI: 7.3 to 24.1), p<0.001. Higher inpatient days by
262	week 10 was associated with poorer VAS score (regression coefficient -0.8, 95% CI -1.1 to -
263	0.4), p<0.001.
264	At month six, the only factor associated with higher VAS score at multivariate analysis was
265	African origin (regression coefficient 12.8 95% CI 2.6 to 23.1), p=0.015. Again, higher
266	inpatient days was associated with a reduced VAS score at 6 months (regression coefficient -
267	0.6, 95% CI -1.0 to -0.3, p=<0.001).
268	
269	

## 270 Table 3: Quality of Life and associated factors at 10 weeks and 6 months

			WEF	CK 10		WEEK SIX				
		Univariate regress	linear ion	Multivariate linear regression		Univariate linear regression		Multivariate linear regression		
Variable	Categories	Reg. Coef. (95% CI)	P Value	Reg. Coef. (95% CI)	P Value*	Reg. Coef. (95% CI)	P Value	Reg. Coef. (95% CI)	P Value*	
Gender	Male									
	Female	6(-2.1 to 14.1)	0.145	6.3(-1.7 to 14.4)	0.122	2.8(-5.2 to 10.8)	0.497			
Age	Cont.	-0.1(-0.5 to 0.4)	0.852			-0.4(-0.9 to 0.2)	0.173	-0.2(-0.7 to 0.3)	0.432	
Years in School	<u>≤</u> 7									
	>7	-0.7(-9 to 7.6)	0.862			-2.2(-10.4 to 5.9)	0.588			
Glasgow	<15									
coma Score	15	7.2(-4.6 to 19.0)	0.230	1.9(-10.4 to 14.2)	0.759	3.7(-8.3 to 15.7)	0.547			
ART at	Yes									
Baseline	No	-6.2(-14.0 to 1.6)	0.121	3.0(-4.9 to 10.8)	0.455	-7.7(-15.4 to 0.03)	0.051	4.1(-5.1 to 13.3)	0.383	
Confusion	Yes									
	No	7.2(-1.7 to 16.1)	0.114	7.5(-2.1 to 17.2)	0.126	-1.2(-10.1 to 7.6)	0.789			
Weight	Cont.	0.5(0.2 to 0.9)	0.005	0.6(0.2 to 1.0)	0.002	0.2(-0.2 to 0.5)	0.397			
Convulsion	Yes									

	No	11.9(0.3 to 23.4)	0.044	-0.8(- 12.2 to 10.5)	0.885	5.5(-6.4 to 17.2)	0.366		
Inpatient days by week 10	Cont.	-0.7(-1.1 to - 0.4)	<0.001	-0.8(-1.1 to -0.4)	<0.001	N/A	N/A		
Inpatient days by month six	Cont.	N/A	N/A	N/A	N/A	-0.5(-0.7 to - 0.2)	< 0.001	-0.6(-1.0 to - 0.3)	<0.001
Intervention	Dexa.								
	Placebo	4.9(-2.9 to 12.6)	0.220	1.4(-6.0 to 8.9)	0.699	5.1(-2.6 to 12.8)	0.193	3.8(-5.0 to 12.6)	0.391
Continent	Asia								
	Africa	18.2(10.8 to 25.6)	< 0.001	15.6(7.3 to 24.1)	< 0.001	14.8(7.4 to 22.2)	< 0.001	12.8(2.6 to 23.1)	0.015
CSF	<1000								
Culture, CFU/ml	≥1000	-6.5(-14.7 to 1.6)	0.116	0.9(-7.1 to 8.9)	0.821	-4.9(-12.9 to 3.1)	0.231	-0.9(-9.7 to 7.9)	0.835
Adverse	None								
events	1-3	-1.0(-10.5 to 8.5)	0.841	5.2(-4.2 to 14.5)	0.277	-3.1(-12.3 to 6.0)	0.498	9.1(-1.6 to 19.8)	0.093
	4+	-10.2(-22.0 to 1.6)	0.09	9(-4.1 to 22.1)	0.177	-10(-22.2 to 2.2)	0.107	15.1(-2.6 to 32.8)	0.094
271	Abbreviatio	ons: ART, Antire	etroviral th	erapy; CI,	Confidence	interval; Reg, I	Regression;	Coef, Coefficient;	
272	Cont. Conti	nuous variable; N	N/A, Not a	applicable; I	Dexa, Dexa	methasone; CFU/	ml, Colony	forming units per	
273	millilitre.								

\* Only variables with a P Value <0.2 in the univariate analysis were used in the multivariable linear regression

275 model.

289			
290			
291			
292			
293			
294			
295			
296			
297			
298			
299			
300			
301			
302			

# 303 **Discussion**

HIV-associated CCM is an extremely debilitating disease associated with high mortality. Affected patients present with advanced HIV disease and considerable immunosuppression. While the disease itself is associated with significant risks of sequelae including neurological deficits, the treatment itself, of which amphotericin is the backbone, is also associated with significant toxicities [18,19]. All these factors have the potential to reduce the QOL among patients who survive up to treatment completion.

We were pleased to see that many patients reported relatively good self-perceived QOL following completion of treatment for CCM, and that this tended to improve thereafter through the 6 months following diagnosis. However, given the nature of the disease and its treatment, it is perhaps not surprising that very few patients reported 'very good' or 'perfect' health. We did not assess the QOL at study entry in the CryptoDex trial and thus could not measure improvement directly attributable to antifungal treatment. However, we found that

316 patients reported significant improvements in QOL between 10 weeks and six months after 317 diagnosis, both with the descriptive and VAS scales. These continuing improvements in QOL 318 are likely due to multiple factors. These may include gradual improvement due to 319 neurological recovery, better engagement with health services, and the use of antiretroviral 320 drugs. A previous study identified that patients with CCM had significant improvements in 321 QOL compared with pre-treatment scores [5]. It has been shown previously that different 322 antifungal combinations can be associated with long term (6 month) differences in 323 survival[9]. Therefore, while some of the improvement in QOL seen in our patients, who all 324 received the same antifungal treatment, may be due to the factors we described above, 325 developing more effective induction and consolidation therapy for CCM is likely to yield 326 further improvements in QOL.

327

328 We consider QOL an important health parameter to measure since better scores have been 329 shown to correlate with long term survival [4,20]. In our study, we used the EQ-5D-3L tool. 330 This has the advantages of simplicity and ease of administration including amongst very sick patients, as well as ease of scoring and interpretation. While it has not been used previously 331 332 in many studies of CCM patients, our work shows that it can identify changes in QOL over 333 time following treatment of CCM. As such, it has the potential to identify patients who may 334 benefit from increased follow-up during the recovery process – further studies are needed. 335 Identifying such patients could help with distribution of scarce resources and ensure the best 336 possible outcomes for all patients.

337

We found that prolonged admission by week 10 and month 6 were associated with lower QOL measured using the VAS at week 10 and month six. This is not surprising - patients

admitted for longer periods were likely more ill at baseline. A similar finding was reported ina study done by Nafteux and colleagues in Belgium [21].

342 We were surprised to see that patients from African countries in the CryptoDex trial rated 343 themselves to have better QOL at week 10 and six months than did Asian patients. This effect 344 was seen with both the descriptive scale and VAS. This effect remained apparent even after 345 adjustment for other factors that affected QOL. We suggest that this is probably a societal 346 perceptual variation rather than an indication of impact of disease, although its inverse 347 correlation with the gross national income per capita for the Asian and African countries was 348 counter-intuitive. We also found that higher weight was associated with higher VAS at week 349 10. The most likely explanation here is that low weight is correlated with more severe disease 350 [22]. Unlike a previous study from Uganda amongst HIV patients that found male gender was 351 associated with better quality of life, we did not identify a difference between males and 352 females in terms of QOL following treatment for CCM [23].

353 Our analysis has some limitations. First, we used a subjective measure of QOL, which may 354 not be an absolute indication of the QOL of an individual. Naturally, optimistic people may 355 rate their health status higher than pessimistic ones. However, the WHO recommends that 356 OOL tools should measure from the subjective viewpoint since the patients experience is 357 more relevant than the assessment of an objective observer [24]. Second, we used health 358 index scores derived from models of countries that we assumed were similar to our own, 359 since models do not exist for all the countries in our study. Use of validated index scores 360 from the actual countries that participated in CryptoDex could conceivably result in different 361 outcomes. However, we think this is unlikely because we measured QOL at two time points 362 and found improvement over time.

Going forward, we would recommend that QOL assessment should be part of all trials in cryptococcal meningitis. Recent work from Molloy and colleagues has suggested that current

doses of amphotericin, which clearly have the greatest antifungal effect, may in fact be resulting in patient harm because of associated toxicities [25]. QOL measurements among survivors could help in parsing such data, while we wait for more effective and tolerable novel treatments to be developed.

## 369 Conclusion

While self-perceived QOL was only relatively good among this cohort of patients who had survived through treatment for CCM, it continued to improve over the 6 months following diagnosis. Low weight at diagnosis, prolonged hospital admission, and being Asian were associated with lower perceived QOL. QOL is an important outcome that should be considered among HIV infected patients treated for serious infections such as CCM.

375

### 376 Acknowledgements

We would like to appreciate the team that implemented the CryptoDex trial at all the sites inAfrica and Asia.

We are especially grateful to the study participants and/or their representatives for the precious time they accorded us.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the supporting agencies.

383

## **384** Author Contributions

Conceived and designed the experiments: Jonathan Kitonsa. Performed the experiments: Jonathan Kitonsa, Freddie Kibengo and Zacchaeus Anywaine. Analysed the data: Julius Kiwanuka, Sheila Katusiime, and Jonathan Kitonsa. Wrote the paper: Jonathan

- 388 Kitonsa, Julius Kiwanuka, Freddie Kibengo, Kenneth Katumba, Zacchaeus Anywaine,
- 389 Pontiano Kaleebu, Alastair Gray, and Jeremy Day.
- 390
- 391
- 392
- 393
- 394
- 395
- 396
- 397 References
- 398

399	1. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, et al. (2014) Effects of
400	early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-
401	1 infection: results from the phase 3 HPTN 052 randomised controlled trial. The
402	Lancet Infectious diseases 14: 281-290.
403	2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009)
404	Estimation of the current global burden of cryptococcal meningitis among persons
405	living with HIV/AIDS. AIDS 23: 525-530.
406	3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, et al. (2017) Global burden
407	of disease of HIV-associated cryptococcal meningitis: an updated analysis. The
408	Lancet Infectious Diseases 17: 873-881.
409	4. Kitonsa J, Mayanja Y, Aling E, Kiwanuka J, Namutundu J, et al. (2019) Factors affecting
410	mortality among HIV positive patients two years after completing recommended
411	therapy for Cryptococcal meningitis in Uganda. PLoS One 14: e0210287.

- 412 5. Mutabazi-Mwesigire D, Katamba A, Martin F, Seeley J, Wu AW (2015) Factors That
- 413 Affect Quality of Life among People Living with HIV Attending an Urban Clinic in
- 414 Uganda: A Cohort Study. PLOS ONE 10: e0126810.
- 6. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, et al. (2011) Life Expectancy of Persons
  Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort
  Analysis From Uganda. Annals of Internal Medicine 155: 209-216.
- 418 7. Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK (2002) Health-Related
- 419 Quality-of-Life Assessments and Patient-Physician CommunicationA Randomized
  420 Controlled Trial. JAMA 288: 3027-3034.
- 8. Degroote S, Vogelaers D, Vandijck DM (2014) What determines health-related quality of
  life among people living with HIV: an updated review of the literature. Archives of
  Public Health 72: 40.
- 9. Day J, Imran D, Ganiem AR, Tjahjani N, Wahyuningsih R, et al. (2014) CryptoDex: a
  randomised, double-blind, placebo-controlled phase III trial of adjunctive
  dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol
  for a randomised control trial. Trials 15: 441.
- 10. Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, et al. (2016) Adjunctive
  Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med 374: 542554.
- 11. Day J, Imran D, Ganiem AR, Tjahjani N, Wahyuningsih R, et al. (2014) CryptoDex: a
  randomised, double-blind, placebo-controlled phase III trial of adjunctive
  dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol
  for a randomised control trial. Trials 15: 441.
- 435 12. Sloan DJ, Parris V (2014) Cryptococcal meningitis: epidemiology and therapeutic
  436 options. Clinical Epidemiology 6: 169-182.

- 437 13. EuroQol (2018) EoroQol Research Foundation. EQ-5D-3L User Guide
- 438 14. WHOQOL Measuring Quality of Life. 1997.
- 439 15. Sirinart Tongsiri JC (2011) Estimating Population-Based Values for EQ-5D Health States
  440 in Thailand. Elsevier.
- 441 16. Jennifer Jelsma KH, Willy de Weerdt, Paul de Cock and Paul Kind (2003) How do
  442 Zimbabweans value health states? BioMed Central.
- 17. Ivanise Arouche Gomes de Souza CCdAP, Andrea Liborio Monteiro (2018) Assessment
  of quality of life using the EQ-5D-3L instrument for hospitalised patients with
  femoral fracture in Brazil. BMC 16.
- 18. Tenforde MW, Wake R, Leeme T, Jarvis JN (2016) HIV-Associated Cryptococcal
  Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings.
  Current clinical microbiology reports 3: 92-102.
- 449 19. Boyer-Chammard T, Temfack E, Alanio A, Jarvis J, Harrison T, et al. (2019) Recent
  450 advances in managing HIV-associated cryptococcal meningitis [version 1; peer
  451 review: 2 approved]. F1000Research 8.
- 20. Cunningham WE, Crystal S, Bozzette S, Hays RD (2005) The Association of Healthrelated Quality of Life with Survival Among Persons with HIV Infection in the
  United States. Journal of General Internal Medicine 20: 21-27.
- 21. Philippe Nafteux JD, Johnny Moons, Willy Coosemans, Georges Decker, Toni Lerut,
  Hans Van Veer, Paul De Leyn (2013) Assessing the relationships between healthrelated quality of life and postoperative length of hospital stay after oesophagectomy
  for cancer of the gastor-oesophageal junction. Eurpean Journal of Cardio-Thoracic
  Surgery 44.

- 460 22. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, Howe PA, White NJ (2001) A
- 461 prospective study of AIDS-associated cryptococcal meningitis in Thailand treated
- with high-dose amphotericin B. The Journal of infection 43: 226.
- 463 23. Mutabazi-Mwesigire D KA, MartinnF, Seeley J, Wu AW (2015) Factors That Affect
- 464 Quality of Life among People Living with HIV Attending an Urban Clinic in Uganda:465 A Cohort Study. PLoS ONE.
- 466 24. WHO. (2020) Health statistics and information systems: Measuring quality of life.
- 467 25. Sile F. Molloy CK, Robert S. Heyderman, Angela Loyse, Duncan Chanda, Sayoki
  468 Mfinanga, Elvis Temfack (2018) Antifungal Combinations for Treatment of
- 469 Cryptococcal Meningitis in Africa. N Engl J Med 378: 1004-1017.



